/clinicaltrials.gov/ct2/show/NCT02625857New immunotherapy agent JNJ-64041809 AKA ADU-741 enters Phase 1 trial for mCRPC. Requiires ADT and 2 prior therapies.
investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&id=2124486Post Edited (robertC) : 12/29/2015 6:57:36 AM (GMT-7)